SI-BONE Q2 revenue up 15.2% to $56.0M; raises FY 2026 revenue guidance to $231M-$233M

SI-BONE, Inc.

Net loss improved 33.6% to $4.1M ($0.09 loss per share) vs $6.2M loss a year ago.
Adjusted EBITDA positive at $2.8M, up 178% from $1.0M in Q2 2025.
U.S. revenue $53.2M (+14.7%); active U.S. physician base grew 19% to 1,715.
FY 2026 revenue guidance raised to $231M-$233M (15-16% growth); operating expense growth lowered to ~12%.
Cash and equivalents $145.9M; positive cash from operations of $0.8M in Q2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.